Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06116617
Registration number
NCT06116617
Ethics application status
Date submitted
30/10/2023
Date registered
3/11/2023
Date last updated
7/02/2024
Titles & IDs
Public title
A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants
Query!
Scientific title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Participants
Query!
Secondary ID [1]
0
0
SRSD107 101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Thrombosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Blood
0
0
0
0
Query!
Clotting disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - SRSD107
Treatment: Drugs - Placebo
Experimental: SRSD107 - SRSD107 for subcutaneous (s.c.) injection Group A1, 15mg, single dose Group A2, 45mg, single dose Group A3, 120mg, single dose Group A4, 240mg, single dose Group A5, 450mg, single dose Group B1, 45mg per dose, 90mg multi dose Group B2, 120mg per dose, 240mg multi dose Group B3, 225mg per dose, 450mg multi dose
Placebo Comparator: Placebo - Sodium chloride for subcutaneous (s.c.) injection
Treatment: Drugs: SRSD107
SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
Treatment: Drugs: Placebo
Sodium chloride
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of adverse events (AEs)
Query!
Assessment method [1]
0
0
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Query!
Timepoint [1]
0
0
up to 168 days post last dose
Query!
Primary outcome [2]
0
0
Proportion of Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
A serious AE (SAE) is defined as any untoward medical occurrence that at any dose either:
results in death
is life threatening
requires inpatient hospitalization or prolongation of existing hospitalization
results in persistent or significant disability/incapacity (disability is defined as a substantial disruption of a person's ability to conduct normal life functions)
results in a congenital anomaly/birth defect
results in an important medical event (see below).
Query!
Timepoint [2]
0
0
up to 168 days post last dose
Query!
Secondary outcome [1]
0
0
Cmax
Query!
Assessment method [1]
0
0
Maximum observed plasma concentration
Query!
Timepoint [1]
0
0
Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31
Query!
Secondary outcome [2]
0
0
tmax
Query!
Assessment method [2]
0
0
Time to maximum plasma concentration
Query!
Timepoint [2]
0
0
Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31
Query!
Secondary outcome [3]
0
0
t1/2
Query!
Assessment method [3]
0
0
Plasma half-life
Query!
Timepoint [3]
0
0
Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31
Query!
Secondary outcome [4]
0
0
AUC
Query!
Assessment method [4]
0
0
Area under the plasma concentration-time curve from 0 to infinity
Query!
Timepoint [4]
0
0
Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31
Query!
Secondary outcome [5]
0
0
CL/F
Query!
Assessment method [5]
0
0
Apparent total clearance
Query!
Timepoint [5]
0
0
Group A, Day 1 to Day 3; Group B, Day 1 to Day 3 and Day 29 to 31
Query!
Secondary outcome [6]
0
0
Effect of SRSD107 on circulating FXI Levels
Query!
Assessment method [6]
0
0
Determination of % Lowering of FXI to Baseline FXI Level
Query!
Timepoint [6]
0
0
up to 168 days post last dose
Query!
Secondary outcome [7]
0
0
Effect of SRSD107 on coagulation
Query!
Assessment method [7]
0
0
Determination of % APTT to baseline APTT
Query!
Timepoint [7]
0
0
up to 168 days post last dose
Query!
Eligibility
Key inclusion criteria
- Body mass index between 18.0 and 32.0 kg/m2, inclusive.
- In good health, based on no clinically significant findings from medical history, 12
lead ECG, vital signs measurements, and clinical laboratory evaluations.
- Activated partial thromboplastin time and PT within the normal range.
- Females will not be pregnant or lactating, and females of childbearing potential and
males will agree to use contraception.
- Able to understand and willing to sign an ICF and to abide by the study restrictions.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Significant history or clinical manifestation of any metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as
determined by the investigator (or designee).
- History or evidence of any abnormal bleeding or coagulation disorder; or evidence of
coagulopathy, prolonged or unexplained, clinically significant bleeding, or frequent
unexplained bruising or thrombus formation; or a history of spontaneous bleeding.
- Evidence of an active or suspected cancer, or a history of malignancy, within 5 years
prior to screening. Nonmelanoma skin cancer, curatively treated localized prostate
cancer, or other carcinoma in situ are not exclusionary, providing that they did not
require systemic therapy and are considered cured.
- Acute of febrile illness within 7 days prior to dose administration or evidence of
active infection.
- Any major surgery within 3 months prior to screening or plan to have any surgery
during the study.
- History of clinically significant hypersensitivity, intolerance, or allergy to any
drug compound, oligonucleotide, GalNAc, food, or other substance, as determined by the
investigator (or designee).
- Confirmed systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg.
- QT interval corrected for heart rate using Fridericia's method (QTcF) >450 ms in males
or >470 ms in females confirmed by repeat measurement.
- White blood cell count <3.5 × 109/L, platelets <100 × 109/L, or hemoglobin below the
lower limit of normal.
- Alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase,
alkaline phosphatase, or total bilirubin >1.5 × the upper limit of normal (ULN).
- Estimated glomerular filtration rate <80 mL/min/1.73m2, as calculated by the 2021
Chronic Kidney Disease Epidemiology Collaboration equation.
- Positive hepatitis panel and/or positive human immunodeficiency virus test.
- Positive pregnancy test at screening or check in.
- Receipt of blood products within 2 months prior to check in.
- Loss of >500 mL whole blood or donation of blood products within 1 month prior to
screening.
- History of intolerance to SC injections, or scarring (eg, from surgical procedures or
burns) in areas when SC dose administration may occur.
- Participants who, in the opinion of the investigator (or designee), should not
participate in this study.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/01/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/08/2025
Query!
Actual
Query!
Sample size
Target
64
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Other (Non U.s.
Query!
Recruitment hospital [1]
0
0
Linear Clinical Research - Perth
Query!
Recruitment postcode(s) [1]
0
0
- Perth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sirius Therapeutics Co., Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate safety and tolerability data when SRSD107
is administered as single and multiple SC injections to healthy participants. This
information, along with PK/PD data, will help establish the appropriate doses and dosing
regimen for future studies in patients.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06116617
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Qiuyue Qu
Query!
Address
0
0
Sirius Therapeutics Co., Ltd.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Qiuyue Qu
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+86 21 61207756
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06116617
Download to PDF